VivoSeq
Musculoskeletal

Lower Extremity Fracture

3

Pipeline Programs↗

2

Active Trials↗

0

Companies Involved↗

Lower Extremity Fracture is an early-stage landscape with 3 programs across 0 companies. 1 therapy is approved.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

6/100

Mech. Concentration

50/100

Completion Rate

0/100

Attrition Rate

33/100

Pipeline

Programs by Phase

Preclinical1

Sufentanil

Leaf Vertical Inc.

Phase 1
No programs
Phase 21

Bupivacaine/exparel

Broward Health

Phase 3
No programs
Approved1

Bupivacaine

Innocoll

Analysis

Trial Status

3

clinical trials

Not yet recruiting2 · 67%
Withdrawn1 · 33%

Clinical Trials

Trial Activity

Sufentanil in Patients With Lower Extremity Fracture Surgery Myocardial Damage Function Study
Not yet recruiting·SSecond Hospital of Shanxi Medical University·N/A·NCT06808841·160 enrolled
Pre-Incision Peripheral Nerve Blocks for Lower Extremity Fracture Surgery in Older Adults
Not yet recruiting·UUniversity of Maryland, Baltimore·Phase 4·NCT07217626·34 enrolled
A Study of Postsurgical Pain Control for Lower Extremity Fractures
Withdrawn·BBroward Health·Phase 1/2·NCT02214810

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)